Drug Type TCR-T Cell therapy |
Synonyms TK 2504, TK-2504 |
Target |
Action inhibitors |
Mechanism KRAS G12V inhibitors(GTPase KRas G12V inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | 01 Sep 2023 |





